| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
ODN-1018 targets Toll-like receptor 9 (TLR9), an intracellular pattern recognition receptor expressed on plasmacytoid dendritic cells and B cells. By binding to TLR9, it activates innate immune signaling pathways (MyD88-dependent), leading to production of pro-inflammatory cytokines and enhanced antigen-specific immune responses.
|
|---|---|
| ln Vitro |
ODN-1018 activates TLR9, leading to the secretion of pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) and upregulation of co-stimulatory molecules (e.g., CD80, CD86) on antigen-presenting cells. It has been shown to induce strong Th1-biased immune responses and has been evaluated for the treatment of allergic asthma and systemic lupus erythematosus.
|
| ln Vivo |
In animal models, ODN-1018 has demonstrated efficacy as a vaccine adjuvant, enhancing immune responses to co-administered antigens. It has also been studied in models of allergic asthma and systemic lupus erythematosus, where its immunomodulatory effects can alter disease progression. Doses and routes vary by study.
|
| Enzyme Assay |
Not applicable. ODN-1018 is an oligonucleotide that activates the intracellular TLR9 receptor. Activity is measured in cell-based TLR9 activation assays, which monitor downstream NF-kappaB activation, cytokine production, or surface marker upregulation.
|
| Cell Assay |
TLR9-expressing reporter cells or primary immune cells (e.g., PBMCs, pDCs) are seeded in 96-well plates. ODN-1018 is added to the culture medium at 0.1-10 ug/mL for 18-24 hours. TLR9 activation is quantified by measuring NF-kappaB-driven luciferase or SEAP activity, or cytokine levels (IL-6, TNF-alpha, IFN-alpha) in the supernatant by ELISA.
|
| Animal Protocol |
In mouse models, ODN-1018 is typically administered via intraperitoneal or subcutaneous injection at doses of 10-100 ug per mouse, either alone or formulated with an antigen. In vaccination studies, it is often co-administered or formulated with the antigen to assess adjuvant activity. Blood and tissues are collected for immune response analysis.
|
| ADME/Pharmacokinetics |
PK data are limited. ODN-1018 is soluble in H2O. It is formulated in endotoxin-free water or PBS for injection. The phosphorothioate backbone provides nuclease resistance. Storage: powder at -20degC for 3 years; in solvent at -80degC for 6 months. Molecular weight: approx. 7150. Sequence: 5'-TGACTGTGAACGTTCGAGATGA-3'.
|
| Toxicity/Toxicokinetics |
Standard oligonucleotide safety precautions apply. ODN-1018 is for research use only, not for human therapy. Avoid inhalation and contact. Use PPE in a well-ventilated area. The compound may cause immunostimulatory adverse effects.
|
| References | |
| Additional Infomation |
This is a research-grade TLR9 agonist. ODN-1018 (also known as 1018 ISS) has been studied in preclinical and clinical settings for use as a vaccine adjuvant, particularly in hepatitis B (HEPLISAV-B) and for immunotherapy of allergic asthma. Purity: ≥98%.
|
| Molecular Formula |
NA MOLECULARWEIGHT
|
|---|---|
| Molecular Weight |
0
|
| CAS # |
937402-51-2
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~13.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
